Biosynthonics For Drug Discovery

Taylor & Francis (expected publication date: December 2015)

It is estimated that of the 10,000-odd protein domains in the human body, all the drug products that have ever been approved by the FDA act on no more than 130 unique domains. This ‘target-rich, lead-poor’ imbalance has, perhaps credibly, led to claims of the demise of small-molecule medicine. However, recent developments in analytics, genome sequencing, flow chemistry, informatics, microbial metabolic engineering, oligonucleotide synthesis and retrosynthetic analysis, as well as exponential improvements in the raw computing power that is now available for drug research, promise brighter prospects for the small-molecule pharmaceutical industry. This book will present a unifying vision called ‘biosynthonics’ that could translate unprecedented numbers of small-molecule drugs to the bedside. Biosynthonics comprises of four principal domains – design, synthesis, exploration and integration. Design encompasses the selection of electronic features and their steric optimization onto a rigid molecular framework in order to ensure optimal binding to a specific biological target. Microbial metabolic engineering will drive synthesis of the desired pharmacophores from carbohydrate-derived building blocks, and the third domain of biosynthonics – exploration – expands the biosynthetic ensemble for metabolic engineering through a systematic search of Nature’s metabolic landscape. The fourth principal activity of biosynthonics – integration – is a modern, biosynthetic take on retrosynthesis, and targets synthesis of an advanced intermediate that can acts as a gateway molecule for target-oriented synthesis (TOS). The nuts and bolts of each domain will be elaborated in considerable detail in this book. Case studies will also be presented.




Organocatalysis in the Fine & Specialty Chemicals Industry

Taylor & Francis (co-edited with Prof. G. D. Yadav, expected publication date: December 2015)

A warming world, the threat of epidemics, our rapidly declining drug stocks, and the inefficiency of current manufacturing processes have forced the industry to reconfigure its operations along the principles of Green Chemistry & Engineering in order to ensure continued economic development while maintaining stewardship of the environment. The new paradigm emphasizes improvement of the atom and energy efficiencies and environmental footprint of manufacturing processes by minimizing the generation of waste, eliminating the use of toxic reagents and solvents, incorporating the use of renewable feedstocks, designing products with enhanced biodegradability, and designing processes that minimize the likelihood of accidents. Catalysis will be central to the new model for chemical manufacturing, especially in the fine and specialty chemicals industry, and heterogeneous, homogeneous, nano- and biocatalysis would have to be combined in truly novel ways to meet this challenge. This multidisciplinary nature of current and future catalysis science will be emphasized in the book. The major themes covered in the book include: (1) new frontiers in catalyst design, (2) nanotechnology and catalysis science, (3) microreactor technologies for synthesis, development and testing of catalysts, (4) biocatalysis, (5) green catalysis science and reaction intensification, (6) current & future applications for catalysis science. The book is a comprehensive collection of key topics in the field of green catalysis science authored by leading practitioners from all around the world.